Immunohelix

Immunohelix, Co., Ltd is a drug discovery company established as a successor of a drug delivery system (DDS) owned by NapaJen Pharma, Inc., a spin-out company from the University of Kitakyushu.  The DDS is based on the triple helix technology composed of nucleic acids and polysaccharides, and the company was named after its core technology.
The company’s proprietary technology enables selective drug delivery to a certain type of immune cell. Utilizing this technology, the company discovers and develops new drugs in various disease areas, such as immunological diseases, infectious diseases, and cancers and so on.